ALFA Filings
Every announcement, straight from the exchange
Every Mankind Pharma acquisition announcement on NSE and BSE, newest first, each with its own page.
Time
4 announcements
Mankind Pharma's board approved amalgamation of two wholly owned subsidiaries into the parent and a step-down subsidiary merger into MCPPL. Schemes require NCLT and shareholder approvals.
Mankind Pharma will invest ₹479.60 Crore into its Dutch subsidiary to acquire a majority 70% stake in Belgian biotech firm ACTx, strengthening its innovation-led portfolio.
Mankind Pharma will acquire a 70% stake in Belgium-based Armed Cell Therapeutics for EUR 48 million to enter the CAR-T therapies market.
Mankind Pharma's subsidiary acquired the remaining 10% stake in Upakarma Ayurveda for ₹0.75 Crore. This transaction makes Upakarma a wholly-owned step-down subsidiary to improve operational efficiencies.